Abstract
It has been reported that peripheral blood T cells and NK cells express reduced levels of the T-cell receptor signal-transducing zeta chain in Hodgkin's disease (HD). The zeta chain has emerged as a key subunit of the T-cell antigen receptor, which plays a central role in the signal-transducing events leading to T and NK-cell activation. We were interested in determining whether the low zeta chain expression in HD could be corrected by anti-CD3, anti-CD3-rIL-2 ex vivo stimulation. Zeta chain expression was analysed by dual immunofluorescence on permeabilized cells before and after 72 hours of culture. The IL-2 concentration in the culture supernatants was measured by ELISA. Zeta chain was significantly reduced on unstimulated CD4+, CD8+ and CD56+ cells from patients in active disease compared with normal subjects. In patients in complete remission, the values were normal except for CD8+ cells, on which zeta expression remained significantly reduced. Stimulation with anti-CD3 did not change zeta expression. Co-stimulation with rIL-2 increased but did not normalize the proportions of CD4+/zeta+, CD8+/zeta+ and CD56+/zeta+ cells and IL-2 production in active disease. Stimulation of cells from patients in clinical remission with anti-CD3+ rIL-2 increased the proportion of CD8+zeta+ cells and normalized IL-2 production levels. Considering the pivotal role of CD3-zeta in immune response, our data suggest that successful immunotherapy approaches in active HD should consider inclusion of other potent cytokines, as well as genetically engineered tumour vaccines. © 2001 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Anderson P, Blue ML, O’Brien C and Schlossman SF (1989) Monoclonal antibodies reactive with T-cell receptor zeta chain: production and characterisation using a new method. J Immunol 143: 1899–1904
Anderson P, Caligiuri M, O’Brien C, Manley T, Ritz J and Schlossman SF (1990) Fc-gamma receptor type III (CD16) is included in zeta NK receptor complex expressed by human natural killer cells. Proc Nat Acad Sci USA 87: 2274–2278
Carbone OO, Kaplan HS, Mushoff K, Smithers DW and Tubiana M (1971) Report of the committee of Hodgkin's disease staging classification. Cancer Res 31: 1860–1870
Farace F, Angevin E, Vanderplancke J, Escudier B and Triebel F (1994) The decreased expression of CD3 zeta chain in cancer patients is not reversed by IL-2 administration. Int J Cancer 59: 752–755
Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'shea JJ, Kudoh S, Klein E, Bukowski RM and Ochoa AC (1993) Loss of T-cell receptor zeta and p56lck in T-cell infiltrating human renal cell carcinoma. Cancer Res 53: 5613–5618
Frydecka I, Kaczmarek P, Bòcko D, Kosmaczewska A and Ciszak L (1998) Alterations in signal-transducing molecule CD3 zeta in patients with neoplastic diseases. Arch Immun Ther Exp 46: 355–359
Frydecka I, Kaczmarek P, Bòcko D, Kosmaczewska A, Morilla R and Catovsky D (1999) Expression of signal-transducing zeta chain in peripheral blood lymphocytes and natural killer cells in patients with Hodgkin's disease in different phases of the disease. Leuk Lymphoma 35: 545–554
Guarini A, Riera L, Cignetti A, Montacchini L, Massaia M and Foa R (1997) Transfer of the interleukin-2 gene into human cancer cells induces specific antitumour recognition and restores the expression of CD3/T receptor associated signal transduction molecules. Blood 1: 212–218
Irving BA and Weiss A (1991) The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathway. Cell 64: 891–901
Kiessling R, Wasserman K, Horiguchi S, Kono K, Sjoberg J, Pisa P and Peterson M (1999) Tumour induced immune dysfunction. Cancer Immunol Immunother 48: 353–362
Matsuda M, Petersson M, Lenkei R, Taupin JL, Magnusson I, Mellstedt H, Anderson P and Kiessling R (1995) Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumour-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int J Cancer 61: 765
Musci MA, Latinis KM and Koretzky GA (1997) Signalling events in T lymphocytes leading to cellular activation or programmed cell death. Clin Immunol Immunopathol 83: 205–222
Nakagomi H, Petersson M, Magnusson L, Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P and Kiessling R (1993) Decreased expression of the signal-transducing zeta chains in tumour infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53: 5610–1612
Rabinowich H, Banks M, Reichert TE, Logan TF, Kirkwood JM and Whiteside TL (1996) Expression and activity of signalling molecules in T lymphocytes obtained from patients with metastatic melanoma before, and after interleukin-2 therapy. Clin Cancer Res 2: 1263–1272
Tartour E, Tartour S, Mathiot C, Thiounn N, Mosser V, Joyeux I, D’Enghien CD, Lee R, Debre B and Fridman WH (1995) Variable expression of CD3 zeta chain in tumour-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63: 205–212
Vivier E, Morin P, O’Brien C, Druker B, Schlossman SF and Anderson P (1991) Tyrosine phosphorylation of the FcRIII CD16: zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol 146: 206–210
Weissman AM, Baniyash M, Hou D, Samelson LE, Burgess WH and Klausner RD (1988) Molecular cloning of the zeta chain of the T cell antigen receptor. Science (Wash.) 239: 1018–1021
Whiteside TL (1999) Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48: 336–352
Yoong KF and Adams DH (1998) Interleukin-2 restores CD3 zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases. Br J Cancer 77: 1072–1081
Zea AH, Brendan D, Curti BD, Longo DL, Alvord GW, Strobi SL, Mizoguchi H, Creekmore SP, O'shea JJ, Powers GC, Urba WJ and Ochoa AC (1995) Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1: 1327–1335
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Frydecka, I., Boćko, D., Kosmaczewska, A. et al. The effect of peripheral blood lymphocyte stimulation on zeta chain expression and IL-2 production in Hodgkin's disease. Br J Cancer 84, 1339–1343 (2001). https://doi.org/10.1054/bjoc.2001.1792
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1792